Literature DB >> 20428196

The prognostic significance of soluble NKG2D ligands in B-cell chronic lymphocytic leukemia.

H Nückel1, M Switala, L Sellmann, P A Horn, J Dürig, U Dührsen, R Küppers, H Grosse-Wilde, V Rebmann.   

Abstract

Soluble or membrane-anchored ligands of NKG2D and their receptor have a critical role in the elimination of tumor cells and disease progression. Plasma samples of 98 patients with B-cell chronic lymphocytic leukemia (CLL) were analyzed with specific ELISA systems for soluble major histocompatibility complex class I-related chains (sMICA and sMICB) and UL-16-binding proteins (ULBP1, 2, and 3). The flow cytometric analysis of MICA on CLL cells and natural killer group 2 member D (NKG2D) receptors on NK cells was performed after thawing of frozen peripheral blood lymphocytes of CLL patients (N=51). Levels of sMICA, sMICB, and sULBP2 were significantly increased (P<0.001) compared with 48 controls, whereas sULBP1 3 were not detectable in patients and controls. Levels of sMICA>990 pg/ml (P=0.014), sMICB>200 pg/ml (P=0.0001), and sULBP2>105 pg/ml (P<0.0001) were associated with poor treatment-free survival (TFS). Neither MICA nor NKG2D expression could be related to clinical parameters. In multivariate analysis Binet stage (P=0.002), sULBP2 (P=0.002) and ZAP-70 (P=0.002) were independent predictive factors for TFS. In patients with Binet stage A, sULBP2 levels>105 pg/ml were strongly associated (P=0.0025) with poor TFS. Our data show that soluble but not membrane-anchored NKG2D ligands or receptors are of prognostic significance in CLL. Moreover, sULBP2 seems to be useful to identify early-stage patients with risk of disease progression.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20428196     DOI: 10.1038/leu.2010.74

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  49 in total

1.  The selenium metabolite methylselenol regulates the expression of ligands that trigger immune activation through the lymphocyte receptor NKG2D.

Authors:  Michael Hagemann-Jensen; Franziska Uhlenbrock; Stephanie Kehlet; Lars Andresen; Charlotte Gabel-Jensen; Lars Ellgaard; Bente Gammelgaard; Søren Skov
Journal:  J Biol Chem       Date:  2014-09-25       Impact factor: 5.157

Review 2.  Recognition of tumors by the innate immune system and natural killer cells.

Authors:  Assaf Marcus; Benjamin G Gowen; Thornton W Thompson; Alexandre Iannello; Michele Ardolino; Weiwen Deng; Lin Wang; Nataliya Shifrin; David H Raulet
Journal:  Adv Immunol       Date:  2014       Impact factor: 3.543

Review 3.  NKG2D ligands as therapeutic targets.

Authors:  Paul Spear; Ming-Ru Wu; Marie-Louise Sentman; Charles L Sentman
Journal:  Cancer Immun       Date:  2013-05-01

4.  NK cell dysfunction in chronic lymphocytic leukemia is associated with loss of the mature cells expressing inhibitory killer cell Ig-like receptors.

Authors:  Alexander W MacFarlane; Mowafaq Jillab; Mitchell R Smith; R Katherine Alpaugh; Marion E Cole; Samuel Litwin; Michael M Millenson; Tahseen Al-Saleem; Adam D Cohen; Kerry S Campbell
Journal:  Oncoimmunology       Date:  2017-05-19       Impact factor: 8.110

5.  Soluble NKG2D ligands are biomarkers associated with the clinical outcome to immune checkpoint blockade therapy of metastatic melanoma patients.

Authors:  Cristina Maccalli; Diana Giannarelli; Carla Chiarucci; Ornella Cutaia; Gianluca Giacobini; Wouter Hendrickx; Giovanni Amato; Diego Annesi; Davide Bedognetti; Maresa Altomonte; Riccardo Danielli; Luana Calabrò; Anna Maria Di Giacomo; Francesco M Marincola; Giorgio Parmiani; Michele Maio
Journal:  Oncoimmunology       Date:  2017-05-08       Impact factor: 8.110

Review 6.  NKG2D and its ligands in cancer.

Authors:  Payal Dhar; Jennifer D Wu
Journal:  Curr Opin Immunol       Date:  2018-03-09       Impact factor: 7.486

7.  Soluble MICA is elevated in pancreatic cancer: Results from a population based case-control study.

Authors:  Guillaume Onyeaghala; Heather H Nelson; Bharat Thyagarajan; Amy M Linabery; Angela Panoskaltsis-Mortari; Myron Gross; Kristin E Anderson; Anna E Prizment
Journal:  Mol Carcinog       Date:  2017-05-24       Impact factor: 4.784

8.  Atypical chronic lymphocytic leukemia with polyglandular autoimmune endocrinopathy type II: a complex profile.

Authors:  Preetesh Jain; Luis Baez-Vallecillo; Yang O Huh; Ohad Benjamini; Lynne Abruzzo; Susan O'Brien; Naveen Pemmaraju; Michael Keating; Robert F Gagel; Zeev Estrov
Journal:  Leuk Lymphoma       Date:  2014-01-24

9.  Mono- and dual-targeting triplebodies activate natural killer cells and have anti-tumor activity in vitro and in vivo against chronic lymphocytic leukemia.

Authors:  Maulik Vyas; Ann-Charlott Schneider; Olga Shatnyeva; Katrin S Reiners; Samir Tawadros; Stephan Kloess; Ulrike Köhl; Michael Hallek; Hinrich P Hansen; Elke Pogge von Strandmann
Journal:  Oncoimmunology       Date:  2016-07-15       Impact factor: 8.110

10.  Soluble ligands for NK cell receptors promote evasion of chronic lymphocytic leukemia cells from NK cell anti-tumor activity.

Authors:  Katrin S Reiners; Daniela Topolar; Alexander Henke; Venkateswara R Simhadri; Jörg Kessler; Maike Sauer; Martina Bessler; Hinrich P Hansen; Samir Tawadros; Marco Herling; Martin Krönke; Michael Hallek; Elke Pogge von Strandmann
Journal:  Blood       Date:  2013-03-18       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.